Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

The interplay of CDK4 and CDK6 in melanoma.

Kollmann K, Briand C, Bellutti F, Schicher N, Blunder S, Zojer M, Hoeller C.

Oncotarget. 2019 Feb 15;10(14):1346-1359. doi: 10.18632/oncotarget.26515. eCollection 2019 Feb 15.

2.

CDK6 coordinates JAK2 V617F mutant MPN via NF-κB and apoptotic networks.

Uras IZ, Maurer B, Nivarthi H, Jodl P, Kollmann K, Prchal-Murphy M, Milosevic Feenstra JD, Zojer M, Lagger S, Grausenburger R, Grabner B, Holly R, Kavirayani A, Bock C, Gisslinger H, Valent P, Kralovics R, Sexl V.

Blood. 2019 Apr 11;133(15):1677-1690. doi: 10.1182/blood-2018-08-872648. Epub 2019 Jan 11.

3.

CDK6 Antagonizes p53-Induced Responses during Tumorigenesis.

Bellutti F, Tigan AS, Nebenfuehr S, Dolezal M, Zojer M, Grausenburger R, Hartenberger S, Kollmann S, Doma E, Prchal-Murphy M, Uras IZ, Höllein A, Neuberg DS, Ebert BL, Ringler A, Mueller AC, Loizou JI, Hinds PW, Vogl C, Heller G, Kubicek S, Zuber J, Malumbres M, Farlik M, Villunger A, Kollmann K, Sexl V.

Cancer Discov. 2018 Jul;8(7):884-897. doi: 10.1158/2159-8290.CD-17-0912. Epub 2018 Jun 13.

4.

Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells.

Streicher C, Heyny A, Andrukhova O, Haigl B, Slavic S, Schüler C, Kollmann K, Kantner I, Sexl V, Kleiter M, Hofbauer LC, Kostenuik PJ, Erben RG.

Sci Rep. 2017 Jul 25;7(1):6460. doi: 10.1038/s41598-017-06614-0.

5.

Oral Macrolides for the Dermatologic Manifestations of Blau Syndrome.

Thareja S, Kollmann K, Ardalan K, Klein-Gitelman MS, Paller AS, Arkin LM.

JAMA Dermatol. 2017 Oct 1;153(10):1066-1067. doi: 10.1001/jamadermatol.2017.2172. No abstract available.

PMID:
28724114
6.

Cdk6 contributes to cytoskeletal stability in erythroid cells.

Uras IZ, Scheicher RM, Kollmann K, Glösmann M, Prchal-Murphy M, Tigan AS, Fux DA, Altamura S, Neves J, Muckenthaler MU, Bennett KL, Kubicek S, Hinds PW, von Lindern M, Sexl V.

Haematologica. 2017 Jun;102(6):995-1005. doi: 10.3324/haematol.2016.159947. Epub 2017 Mar 2.

7.

A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation.

Kollmann K, Warsch W, Gonzalez-Arias C, Nice FL, Avezov E, Milburn J, Li J, Dimitropoulou D, Biddie S, Wang M, Poynton E, Colzani M, Tijssen MR, Anand S, McDermott U, Huntly B, Green T.

Leukemia. 2017 Apr;31(4):934-944. doi: 10.1038/leu.2016.280. Epub 2016 Oct 14.

8.

A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis.

Kollmann K, Heller G, Schneckenleithner C, Warsch W, Scheicher R, Ott RG, Schäfer M, Fajmann S, Schlederer M, Schiefer AI, Reichart U, Mayerhofer M, Hoeller C, Zöchbauer-Müller S, Kerjaschki D, Bock C, Kenner L, Hoefler G, Freissmuth M, Green AR, Moriggl R, Busslinger M, Malumbres M, Sexl V.

Cancer Cell. 2016 Aug 8;30(2):359-360. doi: 10.1016/j.ccell.2016.07.003. Epub 2016 Aug 8. No abstract available.

9.

CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.

Tigan AS, Bellutti F, Kollmann K, Tebb G, Sexl V.

Oncogene. 2016 Jun 16;35(24):3083-91. doi: 10.1038/onc.2015.407. Epub 2015 Oct 26. Review.

PMID:
26500059
10.

Diabetes and Diabetic Retinopathy Management in East Africa: Knowledge, Attitudes, and Practices of Hospital Staff in Kenya.

Kupitz DG, Fenwick E, Kollmann KH, Holz FG, Finger RP.

Asia Pac J Ophthalmol (Phila). 2014 Sep-Oct;3(5):271-6. doi: 10.1097/APO.0b013e3182a83bfa.

11.

Lrp1/LDL Receptor Play Critical Roles in Mannose 6-Phosphate-Independent Lysosomal Enzyme Targeting.

Markmann S, Thelen M, Cornils K, Schweizer M, Brocke-Ahmadinejad N, Willnow T, Heeren J, Gieselmann V, Braulke T, Kollmann K.

Traffic. 2015 Jul;16(7):743-59. doi: 10.1111/tra.12284. Epub 2015 Apr 27.

12.

Mannose 6 phosphorylation of lysosomal enzymes controls B cell functions.

Otomo T, Schweizer M, Kollmann K, Schumacher V, Muschol N, Tolosa E, Mittrücker HW, Braulke T.

J Cell Biol. 2015 Jan 19;208(2):171-80. doi: 10.1083/jcb.201407077.

13.

CDK6 as a key regulator of hematopoietic and leukemic stem cell activation.

Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan AS, Prchal-Murphy M, Heller G, Schneckenleithner C, Salazar-Roa M, Zöchbauer-Müller S, Zuber J, Malumbres M, Kollmann K, Sexl V.

Blood. 2015 Jan 1;125(1):90-101. doi: 10.1182/blood-2014-06-584417. Epub 2014 Oct 23. Erratum in: Blood. 2018 Aug 30;132(9):978-979.

14.

MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling.

Kollmann K, Nangalia J, Warsch W, Quentmeier H, Bench A, Boyd E, Scott M, Drexler HG, Green AR.

Leukemia. 2015 Feb;29(2):494-7. doi: 10.1038/leu.2014.285. Epub 2014 Sep 24. No abstract available.

15.

Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis.

Rodríguez-Díez E, Quereda V, Bellutti F, Prchal-Murphy M, Partida D, Eguren M, Kollmann K, Gómez de Cedrón M, Dubus P, Cañamero M, Martínez D, Sexl V, Malumbres M.

Blood. 2014 Oct 9;124(15):2380-90. doi: 10.1182/blood-2014-02-555292. Epub 2014 Aug 25.

16.

Molecular characterization of arylsulfatase G: expression, processing, glycosylation, transport, and activity.

Kowalewski B, Lübke T, Kollmann K, Braulke T, Reinheckel T, Dierks T, Damme M.

J Biol Chem. 2014 Oct 3;289(40):27992-8005. doi: 10.1074/jbc.M114.584144. Epub 2014 Aug 18.

17.

MicroResearch: finding sustainable local health solutions in East Africa through small local research studies.

MacDonald NE, Bortolussi R, Kabakyenga J, Pemba S, Estambale B, Kollmann KH, Odoi Adome R, Appleton M.

J Epidemiol Glob Health. 2014 Sep;4(3):185-93. doi: 10.1016/j.jegh.2014.01.002. Epub 2014 Feb 21.

18.

Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.

Grundschober E, Hoelbl-Kovacic A, Bhagwat N, Kovacic B, Scheicher R, Eckelhart E, Kollmann K, Keller M, Grebien F, Wagner KU, Levine RL, Sexl V.

Leukemia. 2014 Sep;28(9):1918-22. doi: 10.1038/leu.2014.152. Epub 2014 May 5. No abstract available.

19.

Serine carboxypeptidase SCPEP1 and Cathepsin A play complementary roles in regulation of vasoconstriction via inactivation of endothelin-1.

Pan X, Grigoryeva L, Seyrantepe V, Peng J, Kollmann K, Tremblay J, Lavoie JL, Hinek A, Lübke T, Pshezhetsky AV.

PLoS Genet. 2014 Feb 27;10(2):e1004146. doi: 10.1371/journal.pgen.1004146. eCollection 2014 Feb.

20.

Training trichiasis surgeons: ensuring quality.

Gower EW, Kello AB, Kollmann KhM.

Community Eye Health. 2014;27(87):58. No abstract available.

21.

A hereditary spastic paraplegia mouse model supports a role of ZFYVE26/SPASTIZIN for the endolysosomal system.

Khundadze M, Kollmann K, Koch N, Biskup C, Nietzsche S, Zimmer G, Hennings JC, Huebner AK, Symmank J, Jahic A, Ilina EI, Karle K, Schöls L, Kessels M, Braulke T, Qualmann B, Kurth I, Beetz C, Hübner CA.

PLoS Genet. 2013;9(12):e1003988. doi: 10.1371/journal.pgen.1003988. Epub 2013 Dec 19.

22.

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR.

N Engl J Med. 2013 Dec 19;369(25):2391-2405. doi: 10.1056/NEJMoa1312542. Epub 2013 Dec 10.

23.

Identification of the ubiquitin-like domain of midnolin as a new glucokinase interaction partner.

Hofmeister-Brix A, Kollmann K, Langer S, Schultz J, Lenzen S, Baltrusch S.

J Biol Chem. 2013 Dec 13;288(50):35824-39. doi: 10.1074/jbc.M113.526632. Epub 2013 Nov 1.

24.

CDK6 and p16INK4A in lymphoid malignancies.

Kollmann K, Sexl V.

Oncotarget. 2013 Nov;4(11):1858-9. No abstract available.

25.

Decreased bone formation and increased osteoclastogenesis cause bone loss in mucolipidosis II.

Kollmann K, Pestka JM, Kühn SC, Schöne E, Schweizer M, Karkmann K, Otomo T, Catala-Lehnen P, Failla AV, Marshall RP, Krause M, Santer R, Amling M, Braulke T, Schinke T.

EMBO Mol Med. 2013 Dec;5(12):1871-86. doi: 10.1002/emmm.201302979. Epub 2013 Oct 15.

26.

Ultrastructural analysis of neuronal and non-neuronal lysosomal storage in mucolipidosis type II knock-in mice.

Schweizer M, Markmann S, Braulke T, Kollmann K.

Ultrastruct Pathol. 2013 Oct;37(5):366-72. doi: 10.3109/01913123.2013.810687.

PMID:
24047352
27.

A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis.

Kollmann K, Heller G, Schneckenleithner C, Warsch W, Scheicher R, Ott RG, Schäfer M, Fajmann S, Schlederer M, Schiefer AI, Reichart U, Mayerhofer M, Hoeller C, Zöchbauer-Müller S, Kerjaschki D, Bock C, Kenner L, Hoefler G, Freissmuth M, Green AR, Moriggl R, Busslinger M, Malumbres M, Sexl V.

Cancer Cell. 2013 Aug 12;24(2):167-81. doi: 10.1016/j.ccr.2013.07.012. Erratum in: Cancer Cell. 2016 Aug 8;30(2):359-360.

28.

Cell biology and function of neuronal ceroid lipofuscinosis-related proteins.

Kollmann K, Uusi-Rauva K, Scifo E, Tyynelä J, Jalanko A, Braulke T.

Biochim Biophys Acta. 2013 Nov;1832(11):1866-81. doi: 10.1016/j.bbadis.2013.01.019. Epub 2013 Feb 9. Review.

29.

PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.

Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, Thallinger C, Staber PB, Simonitsch-Klupp I, Artaker M, Lagger S, Turner SD, Pileri S, Piccaluga PP, Valent P, Messana K, Landra I, Weichhart T, Knapp S, Shehata M, Todaro M, Sexl V, Höfler G, Piva R, Medico E, Ruggeri BA, Cheng M, Eferl R, Egger G, Penninger JM, Jaeger U, Moriggl R, Inghirami G, Kenner L.

Nat Med. 2012 Nov;18(11):1699-704. doi: 10.1038/nm.2966. Epub 2012 Oct 14.

30.

Lysosomal dysfunction causes neurodegeneration in mucolipidosis II 'knock-in' mice.

Kollmann K, Damme M, Markmann S, Morelle W, Schweizer M, Hermans-Borgmeyer I, Röchert AK, Pohl S, Lübke T, Michalski JC, Käkelä R, Walkley SU, Braulke T.

Brain. 2012 Sep;135(Pt 9):2661-75. doi: 10.1093/brain/aws209.

31.

Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine in anaplastic large cell lymphoma.

Hassler MR, Klisaroska A, Kollmann K, Steiner I, Bilban M, Schiefer AI, Sexl V, Egger G.

Biochimie. 2012 Nov;94(11):2297-307. doi: 10.1016/j.biochi.2012.05.029. Epub 2012 Jun 9. Review.

32.

Putting the brakes on mammary tumorigenesis: loss of STAT1 predisposes to intraepithelial neoplasias.

Schneckenleithner C, Bago-Horvath Z, Dolznig H, Neugebauer N, Kollmann K, Kolbe T, Decker T, Kerjaschki D, Wagner KU, Müller M, Stoiber D, Sexl V.

Oncotarget. 2011 Dec;2(12):1043-54.

33.

c-JUN prevents methylation of p16(INK4a) (and Cdk6): the villain turned bodyguard.

Kollmann K, Heller G, Sexl V.

Oncotarget. 2011 May;2(5):422-7.

34.

A key enzyme in the biogenesis of lysosomes is a protease that regulates cholesterol metabolism.

Marschner K, Kollmann K, Schweizer M, Braulke T, Pohl S.

Science. 2011 Jul 1;333(6038):87-90. doi: 10.1126/science.1205677.

35.

c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6.

Kollmann K, Heller G, Ott RG, Scheicher R, Zebedin-Brandl E, Schneckenleithner C, Simma O, Warsch W, Eckelhart E, Hoelbl A, Bilban M, Zöchbauer-Müller S, Malumbres M, Sexl V.

Blood. 2011 Apr 14;117(15):4065-75. doi: 10.1182/blood-2010-07-299644. Epub 2011 Feb 7.

36.

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.

Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Hölbl A, Gleixner KV, Dworzak M, Mayerhofer M, Hoermann G, Herrmann H, Sillaber C, Egger G, Valent P, Moriggl R, Sexl V.

Blood. 2011 Mar 24;117(12):3409-20. doi: 10.1182/blood-2009-10-248211. Epub 2011 Jan 10.

37.

Post-translational modifications of the gamma-subunit affect intracellular trafficking and complex assembly of GlcNAc-1-phosphotransferase.

Encarnação M, Kollmann K, Trusch M, Braulke T, Pohl S.

J Biol Chem. 2011 Feb 18;286(7):5311-8. doi: 10.1074/jbc.M110.202382. Epub 2010 Dec 20.

38.

Proteolytic processing of the gamma-subunit is associated with the failure to form GlcNAc-1-phosphotransferase complexes and mannose 6-phosphate residues on lysosomal enzymes in human macrophages.

Pohl S, Tiede S, Marschner K, Encarnação M, Castrichini M, Kollmann K, Muschol N, Ullrich K, Müller-Loennies S, Braulke T.

J Biol Chem. 2010 Jul 30;285(31):23936-44. doi: 10.1074/jbc.M110.129684. Epub 2010 May 19.

39.

A novel single-chain antibody fragment for detection of mannose 6-phosphate-containing proteins: application in mucolipidosis type II patients and mice.

Müller-Loennies S, Galliciotti G, Kollmann K, Glatzel M, Braulke T.

Am J Pathol. 2010 Jul;177(1):240-7. doi: 10.2353/ajpath.2010.090954. Epub 2010 May 14.

40.

Assessment of diabetic retinopathy in newly diagnosed black Kenyan type 2 diabetics.

Nkumbe HE, Kollmann KH, Gaeckle HC.

East Afr Med J. 2010 Mar;87(3):109-14.

PMID:
23057306
41.

Mannose phosphorylation in health and disease.

Kollmann K, Pohl S, Marschner K, Encarnação M, Sakwa I, Tiede S, Poorthuis BJ, Lübke T, Müller-Loennies S, Storch S, Braulke T.

Eur J Cell Biol. 2010 Jan;89(1):117-23. doi: 10.1016/j.ejcb.2009.10.008. Epub 2009 Nov 28. Review.

PMID:
19945768
42.

The Sandwich fellowship: a subspecialty training model for the developing world.

Kassam F, Damji KF, Kiage D, Carruthers C, Kollmann KH.

Acad Med. 2009 Aug;84(8):1152-60. doi: 10.1097/ACM.0b013e3181acf95c.

PMID:
19638787
43.

De novo sulfur SAD phasing of the lysosomal 66.3 kDa protein from mouse.

Lakomek K, Dickmanns A, Mueller U, Kollmann K, Deuschl F, Berndt A, Lübke T, Ficner R.

Acta Crystallogr D Biol Crystallogr. 2009 Mar;65(Pt 3):220-8. doi: 10.1107/S0907444908041814. Epub 2009 Feb 20.

PMID:
19237744
44.

Molecular characterization and gene disruption of mouse lysosomal putative serine carboxypeptidase 1.

Kollmann K, Damme M, Deuschl F, Kahle J, D'Hooge R, Lüllmann-Rauch R, Lübke T.

FEBS J. 2009 Mar;276(5):1356-69. doi: 10.1111/j.1742-4658.2009.06877.x.

45.

Microbial contamination of multi-use ophthalmic solutions in Kenya.

Nentwich MM, Kollmann KH, Meshack J, Ilako DR, Schaller UC.

Br J Ophthalmol. 2007 Oct;91(10):1265-8. Epub 2007 May 2.

46.

JunB is a gatekeeper for B-lymphoid leukemia.

Ott RG, Simma O, Kollmann K, Weisz E, Zebedin EM, Schorpp-Kistner M, Heller G, Zöchbauer S, Wagner EF, Freissmuth M, Sexl V.

Oncogene. 2007 Jul 19;26(33):4863-71. Epub 2007 Feb 12.

PMID:
17297445
47.

Molecular characterization of the hypothetical 66.3-kDa protein in mouse: lysosomal targeting, glycosylation, processing and tissue distribution.

Deuschl F, Kollmann K, von Figura K, Lübke T.

FEBS Lett. 2006 Oct 16;580(24):5747-52. Epub 2006 Sep 22.

48.

Identification of novel lysosomal matrix proteins by proteome analysis.

Kollmann K, Mutenda KE, Balleininger M, Eckermann E, von Figura K, Schmidt B, Lübke T.

Proteomics. 2005 Oct;5(15):3966-78.

PMID:
16145712
49.

Hypertension and stroke--rationale behind the ACCESS trial. Acute Candesartan Cilexetil Evaluation in Stroke Survivors.

Schrader J, Röthemeyer M, Lüders S, Kollmann K.

Basic Res Cardiol. 1998;93 Suppl 2:69-78. Review.

PMID:
9833167
50.

[A contribution on rupture of the large toe stretch tendon].

Kollmann K.

Monatsschr Unfallheilkd Versicher Versorg Verkehrsmed. 1967 Feb;70(2):75-8. German. No abstract available.

PMID:
4230870

Supplemental Content

Loading ...
Support Center